Additional Information
Book Details
Abstract
Diabetes is one of the most important non-communicable lifestyle diseases. Diabetes is a multifaceted disorder which possibly influences and impacts body pathophysiology by different mechanisms and in varied ways. Diabetes has a very distinguished impact on cardiovascular system and plays a detrimental role in development of cardiovascular disorders. Metabolic memory is used to describe the impact of exposure to glucotoxicity, lipotoxicity and other metabolic disturbances, either as an adverse or a beneficial cell response which determines the later development of vascular complications. Terms such as metabolic imprint, legacy effect, glycemic memory or latent hyperglycemic damage are also used. Diabetes has significant impact on different facets of life. Diabetes has a distinguished but significant impact on development of various cancers. Diabetes has a positive, negative and even neutral impact on pathogenesis and progression of cancer depending upon the tumor site. On the contrary, cancer also has a significant effect on diabetes development and management. These facets tend to get overlooked in the study of diabetes development and management. All these aspects are being thoroughly covered in this project so as to facilitate better management of diabetics.
Table of Contents
Section Title | Page | Action | Price |
---|---|---|---|
Front Cover | Front Cover | ||
Front Matter | ia | ||
Copyright | id | ||
ECAB Clinical Update:Diabetology | ie | ||
Hotspots in Diabetes | if | ||
About the Authors | ig | ||
Contents | ii | ||
ECAB Clinical Update InformationHOTSPOTS IN DIABETES | i | ||
Metabolic Memory in Diabetes | 1 | ||
ABSTRACT | 1a | ||
KEYWORDS | 1b | ||
Introduction | 1 | ||
Mechanism of Metabolic Memory | 2 | ||
Clinical Proofs Supporting the Concept of Metabolic Memory | 5 | ||
Clinical Evidence-Type 1 Diabetes | 5 | ||
Clinical Evidence-Type 2 Diabetes | 7 | ||
Therapeutic Aspects | 8 | ||
The Indian Scenario | 9 | ||
Summary | 10 | ||
Key Messages | 10 | ||
Postprandial Hyperglycemia | 13 | ||
ABSTRACT | 13a | ||
KEYWORDS | 13a | ||
Introduction | 13 | ||
The Postprandial Physiology | 14 | ||
Postprandial Hyperglycemia in the Pathogenesis of Type 2 Diabetes | 16 | ||
Consequences and Impact of Postprandial Hyperglycemia | 18 | ||
Mechanisms of Vascular Damage by Postprandial Hyperglycemia | 20 | ||
Abnormal Vasodilation | 20 | ||
Aldolase Reductase Abnormalities | 21 | ||
Glycation | 21 | ||
Hypercoagulability | 21 | ||
Endothelial Inflammatory Activity | 22 | ||
Excess Oxidative Activity | 22 | ||
Treatment Approaches to Postprandial Hyperglycemia | 23 | ||
Diet and Physical Activity | 23 | ||
Pharmacologic Therapy | 24 | ||
Meglitinides | 24 | ||
Disaccharidase Inhibitors | 25 | ||
Exanatide | 26 | ||
Liraglutide | 26 | ||
DPP-IV Inhibitors | 26 | ||
Pramlintide | 26 | ||
Short-acting Insulin Analogs | 26 | ||
Inhaled Insulins | 27 | ||
Summary | 27 | ||
Interrelation of Type 2 Diabetes and Cardiovascular Disease | 32 | ||
ABSTRACT | 32a | ||
KEYWORDS | 32b | ||
Introduction | 32 | ||
Peculiarities In Heart Diseases In Diabetes | 34 | ||
Coronary Artery Disease (CAD) | 34 | ||
Silent Myocardial Ischemia (SMI) | 35 | ||
Congestive Heart Failure (CHF) | 36 | ||
Acute Coronary Syndrome (ACS) | 36 | ||
Pathogenesis of Cvd in Diabetes | 37 | ||
Consequences of Elevated Blood Glucose | 37 | ||
Obesity/Overweight | 38 | ||
Oxidative Stress | 38 | ||
Hypertension | 39 | ||
Dyslipidemia | 39 | ||
Insulin Resistance | 40 | ||
Adipokines | 41 | ||
Endothelial Damage | 41 | ||
Kidney Disease and Microalbuminuria | 42 | ||
Inflammation | 43 | ||
Hypercoagulability | 44 | ||
Treatment/Prevention of Cv Events | 44 | ||
Clinical Trials Aiming To Reducethe The Cvd Risks By Intensive Glycemic Control | 45 | ||
The Controversial Clinical Trials On Glycemic Control | 46 | ||
Clinical Trials Aiming At Reducing Other Cardiovascular Risk Factors | 47 | ||
Summary | 47 | ||
Diabetes and Cancer | 55 | ||
ABSTRACT | 55a | ||
KEYWORDS | 55b | ||
Introduction | 55 | ||
Global Update | 57 | ||
Liver Cancer and Diabetes | 59 | ||
Obesity, Diabetes and Cancer | 61 | ||
Free Fatty Acids | 63 | ||
Chronic Inflammation and Oxidative Stress | 64 | ||
Pancreatic Cancer and Diabetes | 64 | ||
Diabetes and Breast Cancer | 66 | ||
Diabetes and Colon Cancer | 67 | ||
Diabetes and Ovarian Cancer | 68 | ||
Diabetes and Non-Hodgkin's Lymphoma | 68 | ||
Diabetes and Prostate Cancer | 69 | ||
Diabetes and Endometrial Cancer | 70 | ||
Diabetes and Lung Cancer | 72 | ||
Type 1 and Type 2 Diabetes and Cancer | 72 | ||
Hyperinsulinemia/Hyperglycemia in Cancer | 73 | ||
All and Type 1 Diabetes | 77 | ||
Cancer and Statins | 77 | ||
Antidiabetic Drug and Cancer | 79 | ||
Sitagliptin and Pancreatitis | 81 | ||
Liraglutide and Cancer | 82 | ||
Rosiglitazone and Risks of Cancer | 82 | ||
Insulin and Cancer | 82 | ||
Treatment of Cancer and Diabetes | 84 | ||
Diabetes Mellitus and Cancer Treatment Strategies | 86 | ||
Clinical Comments | 89 | ||
Summary and Conclusion | 91 | ||
ECAB Clinical Update: Diabetology Other Books in This Series | 101 | ||
Insulins in Diabetes | 101 | ||
Dietary Considerations in Diabetes | 101 | ||
Cardiometabolic Risk in India | 102 | ||
Glycemic Monitoring | 103 | ||
Microvascular Complications in Diabetes | 104 | ||
Oral Hypoglycemic Agents | 105 | ||
Unconventional Organ Damage in Diabetes | 105 | ||
Diabetes and Lifestyle | 106 | ||
Lipids in Diabetes | 107 |